Jared Davis Huling
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jared Davis Huling has a total of 201 co-authors. Here are the top co-authors by number of shared publications:
- Carolyn T. Bramante
University of Minnesota, Minneapolis, MN, USA
8 shared publications - Guanhua Chen
Department of Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, WI, USA
7 shared publications - Menggang Yu
University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin
7 shared publications - John B. Buse
University of North Carolina School of Medicine, Chapel Hill, USA
5 shared publications Ziren Jiang
Division of Biostatistics and Health Data Science University of Minnesota
4 shared publications- Alayne D. Markland
Division of Geriatrics, Department of Internal Medicine, University of Utah, Salt Lake City, UT; Geriatric Research, Education, and Clinical Center at the Birmingham Veterans Affairs Health Care System; Birmingham, AL
3 shared publications
Latest Publications
- Open Access
- 29 October 2026
- Published by Wiley in Journal of Medical Virology
- Vol. 98 (11)
Metformin at the Time of COVID‐19 Infection and Risk of Long COVID: A Target Trial Emulation Study
Our objective was to evaluate metformin prescribed at the time of SARS‐CoV‐2 infection on the risk of developing Long COVID (LC) in electronic health record data. We conducted a new user analysis of metformin prescribed within 6 days of documented infection with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) versus experimental control: prescription for fluvoxamine, fluticasone, ivermectin, or montelukast. Inclusion criteria: a clinic visit in the 0–6 months and the 6–12 months before infection. Exclusion criteria: metformin or control within 12 months. Primary outcome: LC or death (LC/D), to address death as a competing risk, among patients prescribed drug within Days 0–6 of infection. LC was defined by diagnosis code or computable phenotype. We used entropy balancing to estimate the average treatment effect with a weighted log‐linear model. After weighting, there were 248 in the metformin and control groups; the average age was 53 (16); 16% were Black; and 16% were Hispanic. In the primary analysis, 10/248 (4.0%) in the metformin group developed LC/D versus 21/248 (8.5%) in the control group, adjusted risk ratio (aRR) 0.47 (95% CI 0.25–0.89, p = 0.02). For prescriptions on Days 0–1 relative to infection, aRR was 0.39 (95% CI 0.12–1.24); for prescriptions on Days 0–14, the aRR was 0.75 (95% CI 0.52–1.08). In this observational analysis, metformin prescribed within a week of documented SARS‐CoV‐2 infection was associated with a 53% lower risk of LC over 6 months than comparator medications. With the aRR of 0.47 (95% CI 0.25–0.89), any risk reduction between 75% and 11% is highly compatible with our data. This analysis of electronic health record diagnoses is important for the reproducibility of clinical trial results that ascertained the same outcome but via participant‐report.
- 29 October 2026
- Published by Wiley in Journal of Medical Virology
- Vol. 98 (11)
Open AccessMetformin at the Time of COVID‐19 Infection and Risk of Long COVID: A Target Trial Emulation Study
Our objective was to evaluate metformin prescribed at the time of SARS‐CoV‐2 infection on the risk of developing Long COVID (LC) in electronic health record data. We conducted a new user analysis of metformin prescribed within 6 days of documented infection with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) versus experimental control: prescription for fluvoxamine, fluticasone, ivermectin, or montelukast. Inclusion criteria: a clinic visit in the 0–6 months and the 6–12 months before infection. Exclusion criteria: metformin or control within 12 months. Primary outcome: LC or death (LC/D), to address death as a competing risk, among patients prescribed drug within Days 0–6 of infection. LC was defined by diagnosis code or computable phenotype. We used entropy balancing to estimate the average treatment effect with a weighted log‐linear model. After weighting, there were 248 in the metformin and control groups; the average age was 53 (16); 16% were Black; and 16% were Hispanic. In the primary analysis, 10/248 (4.0%) in the metformin group developed LC/D versus 21/248 (8.5%) in the control group, adjusted risk ratio (aRR) 0.47 (95% CI 0.25–0.89, p = 0.02). For prescriptions on Days 0–1 relative to infection, aRR was 0.39 (95% CI 0.12–1.24); for prescriptions on Days 0–14, the aRR was 0.75 (95% CI 0.52–1.08). In this observational analysis, metformin prescribed within a week of documented SARS‐CoV‐2 infection was associated with a 53% lower risk of LC over 6 months than comparator medications. With the aRR of 0.47 (95% CI 0.25–0.89), any risk reduction between 75% and 11% is highly compatible with our data. This analysis of electronic health record diagnoses is important for the reproducibility of clinical trial results that ascertained the same outcome but via participant‐report.
- Open Access
- 8 June 2026
- Published by Oxford University Press (OUP) in The Gerontologist
- Vol. 66 (7)
Associations of urinary incontinence, absorbent product use, and confidence gained from absorbent product use with perceived ageism in later adulthood
Background and Objectives: Urinary incontinence (UI) has not been examined in relation to perceptions of age discrimination (ageism). This study examined whether UI, absorbent product use, and confidence gained from absorbent product use are associated with ageism in later adulthood. Research Design and Methods: Cross-sectional data were collected from 680 community-dwelling female and male participants. Participants were aged 55–73 years; 62% were women. In 2023–2024, UI, absorbent product use, confidence gained from absorbent product use, and ageism were assessed. Ageism variables (frequency across 7 settings, number of settings, perceived stress of discrimination) were regressed on frequency and severity of UI, absorbent product use frequency, and (among those who used absorbent products) confidence gained from product use. Covariates included age, gender, race, and education. Results: A one standard deviation (SD) greater frequency of UI (Beta = 0.25, 95% CI = 0.18, 0.33), severity of UI (Beta = 0.19, 95% CI = 0.12, 0.27), and frequency of absorbent product use (Beta = 0.12, 95% CI = 0.04, 0.20) were each associated with more frequent exposure to age discrimination across settings. A similar pattern was observed for the number of settings in which participants experienced age discrimination. Frequency and severity of UI and absorbent product use frequency were not associated with perceived stress of discrimination. Confidence gained from absorbent product use was not associated with ageism variables. Discussion and Implications: Longitudinal research is needed to test whether UI-related characteristics are prospectively associated with ageism. Programs and policies are needed to address discriminatory behaviors toward aging individuals in different settings.
- 8 June 2026
- Published by Oxford University Press (OUP) in The Gerontologist
- Vol. 66 (7)
Open AccessAssociations of urinary incontinence, absorbent product use, and confidence gained from absorbent product use with perceived ageism in later adulthood
Background and Objectives: Urinary incontinence (UI) has not been examined in relation to perceptions of age discrimination (ageism). This study examined whether UI, absorbent product use, and confidence gained from absorbent product use are associated with ageism in later adulthood. Research Design and Methods: Cross-sectional data were collected from 680 community-dwelling female and male participants. Participants were aged 55–73 years; 62% were women. In 2023–2024, UI, absorbent product use, confidence gained from absorbent product use, and ageism were assessed. Ageism variables (frequency across 7 settings, number of settings, perceived stress of discrimination) were regressed on frequency and severity of UI, absorbent product use frequency, and (among those who used absorbent products) confidence gained from product use. Covariates included age, gender, race, and education. Results: A one standard deviation (SD) greater frequency of UI (Beta = 0.25, 95% CI = 0.18, 0.33), severity of UI (Beta = 0.19, 95% CI = 0.12, 0.27), and frequency of absorbent product use (Beta = 0.12, 95% CI = 0.04, 0.20) were each associated with more frequent exposure to age discrimination across settings. A similar pattern was observed for the number of settings in which participants experienced age discrimination. Frequency and severity of UI and absorbent product use frequency were not associated with perceived stress of discrimination. Confidence gained from absorbent product use was not associated with ageism variables. Discussion and Implications: Longitudinal research is needed to test whether UI-related characteristics are prospectively associated with ageism. Programs and policies are needed to address discriminatory behaviors toward aging individuals in different settings.
- Open Access
- 23 February 2026
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 41 (10) , 1087-1095
Mortality following atypical femoral fractures in men
Atypical femoral fractures (AFFs) are an uncommon complication of bisphosphonate (BP) treatment for osteoporosis. The purpose of this report was to determine differences in mortality among men treated with BPs who experienced AFFs, hip fractures, or typical subtrochanteric/femoral shaft (ST/FS) fractures. We included men from the Veterans Affairs Corporate Data Warehouse who filled at least one BP prescription over a nearly 20-yr span (October 1, 1999, to December 31, 2022). Typical ST/FS and hip fractures after a first filled prescription for a BP were identified using ICD codes. Radiographic review was conducted for ST/FS fractures to determine which were AFFs using the American Society of Bone and Mineral Research 2014 criterion. Demographic and clinical characteristics and cumulative duration of BP exposure prior to the incident fracture were determined. There were 23 men with an AFF, 4591 with a hip fracture, and 225 with a (non-AFF) ST/FS fracture. At 12-mo post-fracture, 4% of men with an AFF had died, compared with 25% of men with a hip fracture and 15% of men with an ST/FS fracture. Over 5 yrs. of follow-up, mortality following fracture differed among the 3 different fracture groups (χ2 = 6.21, d.f. = 2, p = .045) with death occurring in 7 of 23 (30%) men with an AFF, 2380 of 4591 (52%) men with a hip fracture and 109 of 225 (48%) men with a ST/FS fracture. In Cox proportional hazard models, over 5 yrs, with and without adjustment for covariates, there were no significant differences in mortality following an AFF compared with a hip fracture or an AFF compared with a ST/FS fracture (p > .10 for all). It is possible that mortality is lower following AFF compared with a hip or ST/FS fracture; however, limited sample size among those with AFF may have precluded ascertainment of such a difference.
- 23 February 2026
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 41 (10) , 1087-1095
Open AccessMortality following atypical femoral fractures in men
Atypical femoral fractures (AFFs) are an uncommon complication of bisphosphonate (BP) treatment for osteoporosis. The purpose of this report was to determine differences in mortality among men treated with BPs who experienced AFFs, hip fractures, or typical subtrochanteric/femoral shaft (ST/FS) fractures. We included men from the Veterans Affairs Corporate Data Warehouse who filled at least one BP prescription over a nearly 20-yr span (October 1, 1999, to December 31, 2022). Typical ST/FS and hip fractures after a first filled prescription for a BP were identified using ICD codes. Radiographic review was conducted for ST/FS fractures to determine which were AFFs using the American Society of Bone and Mineral Research 2014 criterion. Demographic and clinical characteristics and cumulative duration of BP exposure prior to the incident fracture were determined. There were 23 men with an AFF, 4591 with a hip fracture, and 225 with a (non-AFF) ST/FS fracture. At 12-mo post-fracture, 4% of men with an AFF had died, compared with 25% of men with a hip fracture and 15% of men with an ST/FS fracture. Over 5 yrs. of follow-up, mortality following fracture differed among the 3 different fracture groups (χ2 = 6.21, d.f. = 2, p = .045) with death occurring in 7 of 23 (30%) men with an AFF, 2380 of 4591 (52%) men with a hip fracture and 109 of 225 (48%) men with a ST/FS fracture. In Cox proportional hazard models, over 5 yrs, with and without adjustment for covariates, there were no significant differences in mortality following an AFF compared with a hip fracture or an AFF compared with a ST/FS fracture (p > .10 for all). It is possible that mortality is lower following AFF compared with a hip or ST/FS fracture; however, limited sample size among those with AFF may have precluded ascertainment of such a difference.
- Open Access
Estimating causal effects of functional treatments with modified functional treatment policies
Functional data are increasingly prevalent in biomedical research. While functional data analysis has been established for decades, causal inference with functional treatments remains largely unexplored. Existing methods typically focus on estimating the causal average dose response functional (ADRF), which requires strong positivity assumptions and offers limited interpretability. In this work, we target a new causal estimand, the modified functional treatment policy (MFTP), which focuses on estimating the average potential outcome when each individual slightly modifies their treatment trajectory from the observed one. A major challenge for this new estimand is the need to define an average over an infinite-dimensional object with no density. By proposing a novel definition of the population average over a functional variable using a functional principal component analysis (FPCA) decomposition, we establish the causal identifiability of the MFTP estimand. We further derive outcome regression, inverse probability weighting, and doubly robust estimators for the MFTP, and provide theoretical guarantees under mild regularity conditions. The proposed estimators are validated through extensive simulation studies. Applying our MFTP framework to the National Health and Nutrition Examination Survey (NHANES) accelerometer data, we estimate the causal effects of reducing disruptive nighttime activity and low-activity duration on all-cause mortality.
Open AccessEstimating causal effects of functional treatments with modified functional treatment policies
Functional data are increasingly prevalent in biomedical research. While functional data analysis has been established for decades, causal inference with functional treatments remains largely unexplored. Existing methods typically focus on estimating the causal average dose response functional (ADRF), which requires strong positivity assumptions and offers limited interpretability. In this work, we target a new causal estimand, the modified functional treatment policy (MFTP), which focuses on estimating the average potential outcome when each individual slightly modifies their treatment trajectory from the observed one. A major challenge for this new estimand is the need to define an average over an infinite-dimensional object with no density. By proposing a novel definition of the population average over a functional variable using a functional principal component analysis (FPCA) decomposition, we establish the causal identifiability of the MFTP estimand. We further derive outcome regression, inverse probability weighting, and doubly robust estimators for the MFTP, and provide theoretical guarantees under mild regularity conditions. The proposed estimators are validated through extensive simulation studies. Applying our MFTP framework to the National Health and Nutrition Examination Survey (NHANES) accelerometer data, we estimate the causal effects of reducing disruptive nighttime activity and low-activity duration on all-cause mortality.
- 6 January 2026
- Published by Oxford University Press (OUP) in Biometrics
- Vol. 82 (1)
A framework for causal estimand selection under positivity violations
Estimating the causal effect of a treatment or health policy with observational data can be challenging due to an imbalance of and a lack of overlap between treated and control covariate distributions. In the presence of limited overlap, researchers choose between (1) methods (e.g., inverse probability weighting) that imply traditional estimands but whose estimators are at risk of considerable bias and variance; and (2) methods (e.g., overlap weighting) which imply a different estimand by modifying the target population to reduce variance. We propose a framework for navigating the tradeoffs between variance and bias due to imbalance and a lack of overlap and the targeting of the estimand of scientific interest. We introduce a bias decomposition that encapsulates bias due to (1) the statistical bias of the estimator; and (2) estimand mismatch, i.e., deviation from the population of interest. We propose two design-based metrics and an estimand selection procedure that help illustrate the tradeoffs between these sources of bias and variance of the resulting estimators. Our procedure allows analysts to incorporate their domain-specific preference for preservation of the original research population versus reduction of statistical bias. We demonstrate how to select an estimand based on these preferences with an application to right heart catheterization data.
- 6 January 2026
- Published by Oxford University Press (OUP) in Biometrics
- Vol. 82 (1)
A framework for causal estimand selection under positivity violations
Estimating the causal effect of a treatment or health policy with observational data can be challenging due to an imbalance of and a lack of overlap between treated and control covariate distributions. In the presence of limited overlap, researchers choose between (1) methods (e.g., inverse probability weighting) that imply traditional estimands but whose estimators are at risk of considerable bias and variance; and (2) methods (e.g., overlap weighting) which imply a different estimand by modifying the target population to reduce variance. We propose a framework for navigating the tradeoffs between variance and bias due to imbalance and a lack of overlap and the targeting of the estimand of scientific interest. We introduce a bias decomposition that encapsulates bias due to (1) the statistical bias of the estimator; and (2) estimand mismatch, i.e., deviation from the population of interest. We propose two design-based metrics and an estimand selection procedure that help illustrate the tradeoffs between these sources of bias and variance of the resulting estimators. Our procedure allows analysts to incorporate their domain-specific preference for preservation of the original research population versus reduction of statistical bias. We demonstrate how to select an estimand based on these preferences with an application to right heart catheterization data.
- Open Access
Data adaptive covariate balancing for causal effect estimation for high dimensional data
A key challenge in estimating causal effects from observational data is handling confounding and is commonly achieved through weighting methods that balance distribution of covariates between treatment and control groups. Weighting approaches can be classified by whether weights are estimated using parametric or nonparametric methods, and by whether the model relies on modeling and inverting the propensity score or directly estimates weights to achieve distributional balance by minimizing a measure of dissimilarity between groups. Parametric methods, both for propensity score modeling and direct balancing, are prone to model misspecification. In addition, balancing approaches often suffer from the curse of dimensionality, as they assign equal importance to all covariates, thus potentially de-emphasizing true confounders. Several methods, such as the outcome adaptive lasso, attempt to mitigate this issue through variable selection, but are parametric and focus on propensity score estimation rather than direct balancing. In this paper, we propose a nonparametric direct balancing approach that uses random forests to adaptively emphasize confounders. Our method jointly models treatment and outcome using random forests, allowing the data to identify covariates that influence both processes. We construct a similarity measure, defined by the proportion of trees in which two observations fall into the same leaf node, yielding a distance between treatment and control distributions that is sensitive to relevant covariates and captures the structure of confounding. Under suitable assumptions, we show that the resulting weights converge to normalized inverse propensity scores in the L2 norm and provide consistent treatment effect estimates. We demonstrate the effectiveness of our approach through extensive simulations and an application to a real dataset.
Open AccessData adaptive covariate balancing for causal effect estimation for high dimensional data
A key challenge in estimating causal effects from observational data is handling confounding and is commonly achieved through weighting methods that balance distribution of covariates between treatment and control groups. Weighting approaches can be classified by whether weights are estimated using parametric or nonparametric methods, and by whether the model relies on modeling and inverting the propensity score or directly estimates weights to achieve distributional balance by minimizing a measure of dissimilarity between groups. Parametric methods, both for propensity score modeling and direct balancing, are prone to model misspecification. In addition, balancing approaches often suffer from the curse of dimensionality, as they assign equal importance to all covariates, thus potentially de-emphasizing true confounders. Several methods, such as the outcome adaptive lasso, attempt to mitigate this issue through variable selection, but are parametric and focus on propensity score estimation rather than direct balancing. In this paper, we propose a nonparametric direct balancing approach that uses random forests to adaptively emphasize confounders. Our method jointly models treatment and outcome using random forests, allowing the data to identify covariates that influence both processes. We construct a similarity measure, defined by the proportion of trees in which two observations fall into the same leaf node, yielding a distance between treatment and control distributions that is sensitive to relevant covariates and captures the structure of confounding. Under suitable assumptions, we show that the resulting weights converge to normalized inverse propensity scores in the L2 norm and provide consistent treatment effect estimates. We demonstrate the effectiveness of our approach through extensive simulations and an application to a real dataset.
- 3 December 2025
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 195 (4) , 1037-1044
Evaluation of potential approaches for counting person-time in instances where no active comparator is present
Emulating the target trial framework in pharmacoepidemiology is challenging when there is no active comparator. We evaluate six approaches to finding surrogate index dates for untreated patients with the goal of identifying one or more solutions that indicate they would give potentially unbiased results. This numerical experiment used 73 070 patients from the MarketScan administrative databases (2013-2019) with type 2 diabetes, first-line therapy with metformin, and second-line therapy with either sodium-glucose cotransporter 2 inhibitors (SGLT2is) or sulfonylureas. Patients taking sulfonylureas were converted into an experimental “untreated” arm. Part 1 sought to find surrogate index dates for the untreated arm. Part 2 compared the experimental estimates of the effect of SGLT2is on cardiovascular disease compared to sulfonylureas, using the surrogate index dates, to the reference estimate. The reference hazard ratio was 0.69. The hazard ratios after the respective approaches for selecting surrogate index dates are as follows: rejection sampling: 0.61, 0.63; median: 1.10, 1.15; prediction model: 0.96; matching algorithm: 1.07. Only the rejection sampling approaches for selecting a surrogate index date provided results which indicate low amounts of potential bias. Extreme care should be taken when making study design decisions for observational research questions that lack an active comparator group.
- 3 December 2025
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 195 (4) , 1037-1044
Evaluation of potential approaches for counting person-time in instances where no active comparator is present
Emulating the target trial framework in pharmacoepidemiology is challenging when there is no active comparator. We evaluate six approaches to finding surrogate index dates for untreated patients with the goal of identifying one or more solutions that indicate they would give potentially unbiased results. This numerical experiment used 73 070 patients from the MarketScan administrative databases (2013-2019) with type 2 diabetes, first-line therapy with metformin, and second-line therapy with either sodium-glucose cotransporter 2 inhibitors (SGLT2is) or sulfonylureas. Patients taking sulfonylureas were converted into an experimental “untreated” arm. Part 1 sought to find surrogate index dates for the untreated arm. Part 2 compared the experimental estimates of the effect of SGLT2is on cardiovascular disease compared to sulfonylureas, using the surrogate index dates, to the reference estimate. The reference hazard ratio was 0.69. The hazard ratios after the respective approaches for selecting surrogate index dates are as follows: rejection sampling: 0.61, 0.63; median: 1.10, 1.15; prediction model: 0.96; matching algorithm: 1.07. Only the rejection sampling approaches for selecting a surrogate index date provided results which indicate low amounts of potential bias. Extreme care should be taken when making study design decisions for observational research questions that lack an active comparator group.
- 1 December 2025
- Published by Institute of Mathematical Statistics in The Annals of Applied Statistics
- Vol. 19 (4) , 2555-2577
Modified treatment policy effect estimation with weighted energy distance
The causal effects of continuous treatments are often characterized through the average dose response function, which is challenging to estimate from observational data due to confounding and positivity violations. Modified treatment policies (MTPs) are an alternative approach that aim to assess the effect of a modification to observed treatment values and work under relaxed assumptions. Estimators for MTPs generally focus on estimating the conditional density of treatment, given covariates, and using it to construct weights. However, weighting using conditional density models has well-documented challenges. Further, MTPs with larger treatment modifications have stronger confounding, and no tools exist to help choose an appropriate modification magnitude. This paper investigates the role of weights for MTPs, showing that, to control confounding, weights should balance the weighted data to an unobserved hypothetical target population that can be characterized with observed data. Leveraging this insight, we present a versatile set of tools to enhance estimation for MTPs. We introduce a distance that measures imbalance of covariate distributions under the MTP and use it to develop new weighting methods and tools to aid in the estimation of MTPs. Using our methods, we study the effect of mechanical power of ventilation on in-hospital mortality.
- 1 December 2025
- Published by Institute of Mathematical Statistics in The Annals of Applied Statistics
- Vol. 19 (4) , 2555-2577
Modified treatment policy effect estimation with weighted energy distance
The causal effects of continuous treatments are often characterized through the average dose response function, which is challenging to estimate from observational data due to confounding and positivity violations. Modified treatment policies (MTPs) are an alternative approach that aim to assess the effect of a modification to observed treatment values and work under relaxed assumptions. Estimators for MTPs generally focus on estimating the conditional density of treatment, given covariates, and using it to construct weights. However, weighting using conditional density models has well-documented challenges. Further, MTPs with larger treatment modifications have stronger confounding, and no tools exist to help choose an appropriate modification magnitude. This paper investigates the role of weights for MTPs, showing that, to control confounding, weights should balance the weighted data to an unobserved hypothetical target population that can be characterized with observed data. Leveraging this insight, we present a versatile set of tools to enhance estimation for MTPs. We introduce a distance that measures imbalance of covariate distributions under the MTP and use it to develop new weighting methods and tools to aid in the estimation of MTPs. Using our methods, we study the effect of mechanical power of ventilation on in-hospital mortality.
- 3 October 2025
- Published by SAGE Publications in Journal of Health Psychology
- Vol. 31 (5) , 2012-2027
Psychosocial risk and protective factors for men’s lower urinary tract symptoms: A secondary analysis of CARDIA cohort study data
This study is a secondary analysis of Coronary Artery Risk Development in Young Adults data examining whether men’s experience of psychosocial factors from baseline (1985–1986), when men were aged 18–30 years, through 25 years of follow-up (2010–2011) are associated with lower urinary tract symptoms (LUTS) in 2012–2013. Consistent with previous literature, adverse childhood family environment (OR = 1.24, 95% CI 1.07, 1.43) and depressive symptoms across early and midlife adulthood (OR = 1.60, 95% CI 1.38, 1.87) were associated with higher numbers of and more severe LUTS, a composite measure. Novel findings demonstrated that interpersonal stressors (OR = 1.24, 95% CI 1.07, 1.44) and other life stressors (OR = 1.33, 95% CI 1.15, 1.53) in early and midlife adulthood were associated with worse LUTS among men, while emotional support was protective (OR = 0.69, 95% CI 0.60, 0.81). Findings suggest that a variety of psychosocial experiences may influence LUTS. Additional research is needed to confirm novel findings and identify mechanisms by which life course psychosocial factors may influence the development, maintenance, or worsening of LUTS.
- 3 October 2025
- Published by SAGE Publications in Journal of Health Psychology
- Vol. 31 (5) , 2012-2027
Psychosocial risk and protective factors for men’s lower urinary tract symptoms: A secondary analysis of CARDIA cohort study data
This study is a secondary analysis of Coronary Artery Risk Development in Young Adults data examining whether men’s experience of psychosocial factors from baseline (1985–1986), when men were aged 18–30 years, through 25 years of follow-up (2010–2011) are associated with lower urinary tract symptoms (LUTS) in 2012–2013. Consistent with previous literature, adverse childhood family environment (OR = 1.24, 95% CI 1.07, 1.43) and depressive symptoms across early and midlife adulthood (OR = 1.60, 95% CI 1.38, 1.87) were associated with higher numbers of and more severe LUTS, a composite measure. Novel findings demonstrated that interpersonal stressors (OR = 1.24, 95% CI 1.07, 1.44) and other life stressors (OR = 1.33, 95% CI 1.15, 1.53) in early and midlife adulthood were associated with worse LUTS among men, while emotional support was protective (OR = 0.69, 95% CI 0.60, 0.81). Findings suggest that a variety of psychosocial experiences may influence LUTS. Additional research is needed to confirm novel findings and identify mechanisms by which life course psychosocial factors may influence the development, maintenance, or worsening of LUTS.
- Open Access
Exploring the effects of mechanical ventilator settings with modified vector-valued treatment policies
Mechanical ventilation is critical for managing respiratory failure, but inappropriate ventilator settings can lead to ventilator-induced lung injury (VILI), increasing patient morbidity and mortality. Evaluating the causal impact of ventilator settings is challenging due to the complex interplay of multiple treatment variables and strong confounding due to ventilator guidelines. In this paper, we propose a modified vector-valued treatment policy (MVTP) framework coupled with energy balancing weights to estimate causal effects involving multiple continuous ventilator parameters simultaneously in addition to sensitivity analysis to unmeasured confounding. Our approach mitigates common challenges in causal inference for vector-valued treatments, such as infeasible treatment combinations, stringent positivity assumptions, and interpretability concerns. Using the MIMIC-III database, our analyses suggest that equal reductions in the total power of ventilation (i.e., the mechanical power) through different ventilator parameters result in different expected patient outcomes. Specifically, lowering airway pressures may yield greater reductions in patient mortality compared to proportional adjustments of tidal volume alone. Moreover, controlling for respiratory-system compliance and minute ventilation, we found a significant benefit of reducing driving pressure in patients with acute respiratory distress syndrome (ARDS). Our analyses help shed light on the contributors to VILI.
Open AccessExploring the effects of mechanical ventilator settings with modified vector-valued treatment policies
Mechanical ventilation is critical for managing respiratory failure, but inappropriate ventilator settings can lead to ventilator-induced lung injury (VILI), increasing patient morbidity and mortality. Evaluating the causal impact of ventilator settings is challenging due to the complex interplay of multiple treatment variables and strong confounding due to ventilator guidelines. In this paper, we propose a modified vector-valued treatment policy (MVTP) framework coupled with energy balancing weights to estimate causal effects involving multiple continuous ventilator parameters simultaneously in addition to sensitivity analysis to unmeasured confounding. Our approach mitigates common challenges in causal inference for vector-valued treatments, such as infeasible treatment combinations, stringent positivity assumptions, and interpretability concerns. Using the MIMIC-III database, our analyses suggest that equal reductions in the total power of ventilation (i.e., the mechanical power) through different ventilator parameters result in different expected patient outcomes. Specifically, lowering airway pressures may yield greater reductions in patient mortality compared to proportional adjustments of tidal volume alone. Moreover, controlling for respiratory-system compliance and minute ventilation, we found a significant benefit of reducing driving pressure in patients with acute respiratory distress syndrome (ARDS). Our analyses help shed light on the contributors to VILI.